Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Immunohistochemical and genetic profiles do not predict behavior of mixed hepatocellular intrahepatic cholangiocarcinoma.
Authors
Santiago Sucre
Beth Israel Deaconess Medical Center, Boston, MA;
Santiago Sucre , Rodrigo Paredes , Mary Linton Bounetheau Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 516)
DOI
10.1200/JCO.2023.41.4_suppl.516
Abstract #
516
Poster Bd #
B6
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Exploring the genomic landscape of hepatobiliary cancers to establish a novel molecular subtype classification.
First Author: Anthony Joseph Scholer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma.
First Author: Tin-Yun Tang
Poster
2018 Gastrointestinal Cancers Symposium
Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing.
First Author: Jianzhen Lin
Poster
2018 Gastrointestinal Cancers Symposium
The impact of tumor genomic profile on the effectiveness of adjuvant chemotherapy in resectable intrahepatic cholangiocarcinoma.
First Author: Rebecca Marcus